Compare HTZ & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HTZ | COLL |
|---|---|---|
| Founded | 1918 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Rental/Leasing Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.5B |
| IPO Year | 1997 | 2015 |
| Metric | HTZ | COLL |
|---|---|---|
| Price | $5.21 | $47.18 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | $5.05 | ★ $47.50 |
| AVG Volume (30 Days) | ★ 5.9M | 490.1K |
| Earning Date | 02-12-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.63 |
| Revenue | ★ $8,516,000,000.00 | $757,067,000.00 |
| Revenue This Year | N/A | $26.35 |
| Revenue Next Year | $3.35 | $3.67 |
| P/E Ratio | ★ N/A | $30.44 |
| Revenue Growth | N/A | ★ 26.34 |
| 52 Week Low | $3.26 | $23.23 |
| 52 Week High | $9.39 | $50.79 |
| Indicator | HTZ | COLL |
|---|---|---|
| Relative Strength Index (RSI) | 47.84 | 49.12 |
| Support Level | $5.13 | $48.50 |
| Resistance Level | $5.38 | $50.79 |
| Average True Range (ATR) | 0.25 | 1.33 |
| MACD | 0.03 | -0.39 |
| Stochastic Oscillator | 26.40 | 20.92 |
Hertz Global Holdings Inc is engaged principally in the business of renting vehicles through Hertz, Dollar and Thrifty brands. The Company has identified two reportable segments: Americas RAC: Rental of vehicles, as well as sales of vehicles and value-added services, in the U.S., Canada, Latin America and the Caribbean; International RAC: Rental of vehicles, as well as sales of vehicles and value-added services, in locations other than the U.S., Canada, Latin America and the Caribbean. The Company maintain a substantial network of company-operated rental locations, a majority of which are in Europe, and have franchisees and partners that operate rental locations under brands. Geographical markets includes U.S., Europe, Pacific Asia, Middle East and Africa, Latin America.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.